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The Glycoprotein IIb Molecule Is Expressed
on Early Murine Hematopoietic Progenitors and
Regulates Their Numbers in Sites of Hematopoiesis
quent cell-restricted metabolic suicide (Tronik-Le Roux
et al., 1995; Tropel et al., 1997). More recently, it has
been shown that GPIIb is expressed on immature hema-
topoietic cells in chick and mouse embryos, including
sites of stem cell emergence (Corbel and Salaun, 2002;
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Ody et al., 1999). It has also been detected on human
cord blood and bone marrow progenitors (Debili et al.,
2001) and on more than 80% of progenitors from ES cell-Summary
derived embryoid bodies (Mitjavila-Garcia et al., 2002).
Here, we describe results that shed additional lightThe  integrin GPIIb is a marker of hematopoietic pro-
on the developmental expression of GPIIb on hemato-genitors. Using a marking strategy based on Cre-loxP
poietic progenitors and reveal a function for this mole-technology to trace the fate of GPIIb-expressing cells,
cule in the regulation of hematopoiesis. Using gpIIb pro-we show that GPIIb is expressed during early definitive
moter-driven Cre recombinase to activate-galactosidaseembryonic hematopoiesis. However, the marked fetal
gene expression through deletion of a LoxP-flanked tran-population is distinct from the hematopoietic cells that
scriptional block in the R26R reporter line (Soriano, 1999),predominate in the adult, suggesting that at least two
we provide evidence for expression of gpIIb in early hema-waves of progenitors arise concurrently or consecu-
topoiesis. Mature myeloid and lymphoid cells in the fetustively in the fetus. Furthermore, using an inactivated
are marked with the recombined R26R allele, even thoughallele of gpIIb, we provide evidence for a functional
Cre recombinase is inactive in mature cells, suggestingrole of GPIIb on progenitors. We observe an increase
that the gpIIb gene is expressed in a common hematopoi-in hematopoietic progenitors in the yolk sac, fetal liver,
etic progenitor. We also generated a null allele for theand bone marrow, an effect which may, in part, be
gpIIb gene and, through analysis of homozygous mice,explained by loss of binding to fibronectin.
we demonstrate a functional role for GPIIb in the regulation
of progenitor cell number in the yolk sac, fetal liver, andIntroduction
bone marrow. In the absence of GPIIb, we observed a
consistent increase in hematopoietic progenitors through-The purification of hematopoietic stem cells and multi-
out development. Our results suggest that the loss of GPIIbpotential progenitors is an ongoing challenge (Lem-
is associated with decreased function of VLA-4 and VLA-5ischka, 1991; Spangrude et al., 1991). The need for addi-
in mediating the adhesion of hematopoietic progenitorstional markers is ever important since even though
to bone marrow-derived stroma and to fibronectin.antigen markers such as Sca-1, c-kit, CD34, and AA4.1
are routinely used to sort early hematopoietic cells (Mor-
Resultsrison and Weissman, 1994), they are not absolutely spe-
cific to these cells (Cumano and Godin, 2001). Con-
Generation and Characterizationversely, early hematopoietic expression of markers once
of gpIIb-Cre Transgenicsbelieved to be restricted to mature cell types is often
Our first approach in investigating the role of GPIIb inobserved. For instance, the integrin CD11b was origi-
hematopoietic cells was to generate transgenic mousenally defined as a macrophage lineage marker but is
lines expressing Cre recombinase under the control of thenow known to be expressed on a subset of fetal liver
gpIIb promoter. We used 2.5 kbp of the gpIIb promoter,progenitors (Morrison et al., 1995). More recently, the
previously shown to be sufficient for transgenic expressionglycoprotein IIb molecule (GPIIb), which is part of the
(Tropel et al., 1997), and 2.8 kbp of the gpIIb first intronGPIIb/IIIa (IIb3 or CD41/CD61) integrin complex and
(Figure 1A). Five transgenic lines were generated with copywas viewed as the classical megakaryocyte- and plate-
number varying from 2 to 5. One of the lines did notlet-specific marker (Ginsberg et al., 1995), has also been
express Cre while the other four showed similar patternsrecognized as a hematopoietic progenitor marker.
of expression but at different levels (data not shown). LineEarly results using anti-platelet antibodies suggested
NE1/21 was selected for experimental use.that GPIIb was present on multipotential myeloid pro-
gpIIb-Cre transgene expression in NE1/21 was deter-genitors (Berridge et al., 1985; Fraser et al., 1986) while
mined by crossing it to the ROSA-26 (R26R) reporter linestudies on cycling CD34 progenitors showed that they
and analyzing the extent of recombination in offspringexpressed gpIIb RNA (Debili et al., 1992). These results
throughout development by whole-mount -galactosi-were supported by the observation of reduced numbers
dase staining. Cre-mediated recombination in doubleof CFU-GEMM in mice carrying a gpIIb-tk transgene
transgenic gpIIb-Cre::R26R embryos was seen as palefollowing administration of gangcyclovir and conse-
-galactosidase staining in the yolk sac blood islands
at E8.5 with a punctate pattern revealing that only a
*Correspondence: emambokus@bloodgroup.tch.harvard.edu few cells were positive (Figure 1B). A few circulating1Present address: Division of Hematology-Oncology, Children’s
-galactosidase-positive cells were also seen in the de-Hospital, Boston, Massachusetts 02115.
veloping E8.5 aorta (inset on the top right of Figure 1B).2Present address: Department of Anatomy, Birmingham Medical
School, Birmingham B15 2TT, United Kingdom. By E9.5 gpIIb-Cre::R26R embryos contained -galactosi-
Immunity
34
Figure 1. Generation and Characterization of the gpIIb-Cre Tg Line
(A) Structure of the gpIIb-Cre transgene. The first exon of the murine gpIIb gene is depicted as a black box. The lines represent promoter
and intron 1 sequences. SA, splice acceptor; IRES, internal ribosome entry site; CreNLS, fusion protein between the Cre recombinase sequences
and the SV40 nuclear localization signal; pA, cytomegalovirus (CMV) polyadenylation site. BamHI (B), EcoRI (E), HindIII (H), and NotI restriction
endonuclease sites are depicted.
(B) Cross-section of a gpIIb-Cre Tg::R26R E8.5 embryo showing staining for -galactosidase activity in cells of the yolk sac blood islands.
The inset (upper right corner) shows a -galactosidase-positive circulating blood cell in the aorta.
(C) Whole-mount staining of a gpIIb-Cre Tg::R26R E9.5 embryo showing -galactosidase-positive cells in the aorta. The inset (lower left corner)
shows a -galactosidase-positive cell budding off from the endothelium of a blood vessel.
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dase-positive cells in the aorta-gonad-mesonephros expression, we compared -galactosidase expression
(AGM) region, a putative site of stem cell emergence in gpIIb-Cre::R26R embryos to whole-mount antibody
(Cumano and Godin, 2001), in particular in the dorsal detection of GPIIb. At E9.5, the pattern of GPIIb expres-
aorta (Figure 1C). The number of -galactosidase-posi- sion matched -galactosidase expression in gpIIb-
tive cells increased dramatically by E10.5 in the circula- Cre::R26R embryos, both being expressed in the aorta
tion and in the fetal liver (Figure 1E). Endothelial cells (Figure 3A). However, by E10.5 the pattern of GPIIb ex-
did not express -galactosidase except for a few cells pression only partially overlapped with that of
with rounded appearance that appeared to be “budding” -galactosidase expression in gpIIb-Cre::R26R em-
from the floor of the aorta. Such cells could be detected bryos. GPIIb was detected in the AGM region and in a
from E9.5 onward (inset to the left of Figure 1C), had few cells of the fetal liver (data not shown) whereas
a similar appearance to the intraarterial GPIIb clusters stronger -galactosidase staining was detected in the
reported at E10 (Corbel and Salaun, 2002), and were con- AGM region and in the majority of E10.5 fetal liver cells
firmed to be hematopoietic (data not shown). By E12.5, in gpIIb-Cre::R26R embryos (Figure 1E). These results
the majority of the developing fetal liver and circulating matched previous studies of GPIIb expression (Corbel
blood cells were -galactosidase positive (Figure 1F). At and Salaun, 2002) and suggested that GPIIb is present
E18.5, the embryonic thymus, spleen, bone marrow, and on cells corresponding to the hematopoietic progeni-
circulating blood cells were -galactosidase positive (Fig- tors present in the AGM and fetal liver and that
ures 1H–1J). -galactosidase expression in gpIIb-Cre::R26R em-
Further analysis of gpIIb-Cre::R26R E9.5 AGM and bryos not only reflects this but also marks the descen-
yolk sac and of E12.5 fetal liver confirmed that a substan- dants of these progenitors.
tial proportion of hematopoietic cells carried the recom- We were concerned that Cre might be expressed from
bined R26R allele. Correlating with the histological stain- the gpIIb-Cre in all hematopoietic cells rather than being
ings, flow cytometric analysis of total hematopoietic a reflection of endogenous gpIIb expression. We there-
cells from E9.5 using fluorescein di--D-galactopyrano- fore performed whole-mount staining of E10.5 gpIIb-
side (FDG) as the substrate for -galactosidase revealed
Cre::R26R embryos and immunohistochemistry on
that 64% of that population contained the recombined
E12.5 gpIIb-Cre::R26R fetal liver sections using an anti-
R26R allele (Figure 1D). Of the E9.5 FDG, 5.4%, 3.1%,
body against Cre. Expression could be observed in theand 4.1% were positive for CD41, CD34, and c-Kit, re-
AGM region at E10.5 (Figure 3B), coinciding with GPIIbspectively (data not shown). By E12.5 more than 60%
expression and only partially overlapping with-galactosi-of the fetal liver cells contained the recombined R26R
dase expression in equivalent embryos. At E12.5, Creallele (Figure 1F), and of these 10.6%, 43.9%, and 7.4%
expression could only be detected in a few cells of thewere positive for expression of c-Kit, the erythroid
fetal liver as shown in Figure 3C.marker Ter119, and the hematopoietic marker CD45,
These results demonstrate that GPIIb is expressed atrespectively (Figure 1G). Similar analyses of cells from
the site of emergence of hematopoietic progenitors inE18.5 fetal bone marrow, spleen, and thymus revealed
the yolk sac, AGM, and fetal liver, and that this expres-that 21.4%, 15.6%, and 54.6%, respectively, were posi-
sion is mirrored by Cre expression in gpIIb-Cre embryos.tive for expression of -galactosidase (Figures 1H–1J).
By mediating recombination of the R26R allele, this pat-In contrast, in a 2-month-old adult the number of
tern of Cre expression leads to the marking of the de--galactosidase-positive cells had fallen to 4%, 3%,
scendant definitive fetal liver hematopoietic cells.and 1% in the bone marrow, spleen, and thymus, re-
spectively (Figures 1K–1M).
Generation of a gpIIb Null AlleleAnalysis of genomic DNA from E12.5 and E14.5 gpIIb-
As part of our Cre-LoxP cell-marking strategy, we alsoCre::R26R fetal liver confirmed that the R26R locus had
generated a null allele of the gpIIb gene (gpIIbGFPCre).been recombined in over 90% of cells while in other
Sequences encoding a GFPCre fusion protein were in-tissues only trace recombination could be detected (Fig-
troduced into the first intron of the gpIIb locus by geneure 2A and data not shown). However, analysis of DNA
targeting. An artificial splice acceptor site fused to anfrom gpIIb-Cre::R26R adult bone marrow showed that
internal ribososomal entry site (IRES) was placed up-less than 5% of the cells contained a recombined R26R
stream of the GFPCre sequences to enable splicing andlocus (Figure 2B).
translation of GFPCre. A PGK-neo cassette flanked by
Flp-recombinase target sites (FRT) was inserted down-Expression of GPIIb and Cre Recombinase
stream of the GFPCre cassette in the first intron for theTo determine whether Cre-mediated recombination of
the R26R locus by gpIIb-Cre reflected endogenous gpIIb purpose of selection during ES cell targeting (Figure 4A).
(D) Histograms depicting flow cytometric analysis of -galactosidase activity in R26R (upper panel) and gpIIb-Cre Tg::R26R E9.5 (lower panel)
hematopoietic cells loaded with FDG (solid lines) compared to cells incubated without substrate (dashed lines).
(E) Whole-mount staining of a gpIIb-Cre Tg::R26R E10.5 embryo showing -galactosidase-positive cells in the fetal liver and in the circulation.
(F) Cross-section through a gpIIb-Cre Tg::R26R E12.5 fetal liver showing that the majority of the cells stain positive for -galactosidase activity.
Below are shown corresponding flow cytometric analyses of -galactosidase activity in R26R (left) and gpIIb-Cre Tg::R26R E12.5 (right) as
described in (D).
(G) Histograms depicting flow cytometric analyses of gpIIb-Cre Tg::R26R E12.5 fetal liver cells loaded with FDG after staining for expression
of c-kit, Ter119, or CD45 using specific biotin-conjugated monoclonal antibodies and streptavidin-PE.
(H–J) Cross-sections through E18.5 gpIIb-Cre Tg::R26R femur (H), spleen (I), and thymus (J) stained for -galactosidase activity. The adjacent
histograms depict flow cytometric analyses for -galactosidase activity as described in (D).
(K–M) Flow cytometric analyses for -galactosidase activity in adult bone marrow (K), spleen (L), and thymus (M) as described in (D).
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Figure 2. Characterization of GPIIb and Cre Recombinase Expression
(A) Expression of GPIIb in E9.5 embryos. Whole-mount staining of embryos was performed using rabbit polyclonal anti-GPIIb (right panel) or
a matched nonspecific control (left). The arrow indicates positive staining in the region corresponding to the location of the AGM. Some
nonspecific staining or reagent accumulation can be seen in the tail region.
(B) Expression of Cre recombinase in E10.5 embryos. Whole-mount staining of embryos was performed using rabbit polyclonal anti-Cre (right)
or a matched nonspecific control (left). The arrow indicates positive staining in the region corresponding to the location of the AGM. Nonspecific
staining was observed in the head, tail, and limb buds.
(C) Immunohistochemical detection of Cre in E12.5 gpIIb-Cre Tg::R26R fetal liver. Fetal liver from an embryo which had been stained for
-galactosidase activity (see Figure 1F) was sectioned and labeled using rabbit polyclonal anti-Cre (right) or a matched nonspecific control
(left). Specific binding was revealed using a secondary HRP-conjugated anti-rabbit antibody.
gpIIbGFPCre/GFPCre homozygotes are viable and fertile al- was relatively low expression of the fusion protein. In
crosses with R26R we only obtained recombination inthough they have dysfunctional platelets and occasion-
ally anemia because of the resulting bleeding tendancy about 10% of megakaryocytes (unpublished data).
(N.R. Emambokus et al., submitted). No GPIIb protein
could be detected on bone marrow cells from
gpIIbGFPCre/GFPCre homozygotes either by flow cytometry
using a monoclonal antibody specific to CD41 (Figure
4C, upper panels) or by Western blotting analysis using
polyclonal anti-GPIIb (data not shown). However, since
the number of CD41 cells is normally low (approxi-
mately 2.5% of adult bone marrow) and to exclude the
possibility that the gpIIbGFPCre allele was expressed at
lower levels than its wild-type counterpart, we cultured
wild-type and gpIIbGFPCre/GFPCre bone marrow cells under
conditions allowing the selective outgrowth of megakar-
yocytes. Flow cytometric analysis of cells grown under
these conditions showed that up to 49% of the wild-
type cells were CD41 while none could be detected in
cultures of gpIIbGFPCre/GFPCre bone marrow (Figure 4C,
Figure 3. Detection of Deletion in Tissues from gpIIb-Cre Tg::R26Rlower panels). Analysis of wild-type and gpIIbGFPCre/GFPCre
Embryos and Adultshematopoietic tissues during development also re-
Genomic DNA was digested with EcoRV, Southern blotted, andvealed that, while wild-type E9.5 yolk sac and E12.5 fetal
probed with a 500 bp ROSA26-specific probe.liver contained 12% and 4% of CD41 cells, respec-
(A) Analysis of DNA from wild-type (lane 1), R26R (lane 2), and gpIIb-
tively, none could be detected in the equivalent tissues Cre Tg::R26R (lane 3) E14.5 embryonic fetal liver and hind limbs/
from gpIIbGFPCre/GFPCre embryos (data not shown). tail of the same embryos. The wild-type (ROSA26) and modified
(R26R) alleles yield EcoRV fragments of 11 and 3.8 kbp, respectively.In contrast to the gpIIb-Cre line, expression of Cre
Recombination mediated by Cre reduces the modified allele EcoRVfrom the gpIIbGFPCre allele was restricted to the megakary-
fragment to 3.3 kbp. Recombination in the gpIIb-Cre Tg::R26R fetalocyte lineage (unpublished data). Although we could
liver was over 90% complete (third lane) compared to 10% in thedetect Cre by Western blotting of cultured megakaryo-
tissues derived from the lower body.
cytes (data not shown), we could not detect GFP fluores- (B) Analysis of DNA from bone marrow cells derived from R26R (lane
cence, suggesting either that the GFP moiety (unen- 1) and gpIIb-Cre Tg::R26R (lane 2) adults. Recombination of the
R26R locus can barely be detected in gpIIb-Cre Tg::R26R.hanced version) was too weakly fluorescent or that there
A Function for GPIIb on Hematopoietic Progenitors
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Figure 4. Generation of a Null gpIIb (gpIIbGFPCre) Allele
(A) Schematic representation of the wild-type gpIIb allele showing the promoter and the first 13 exons. Also shown are the gpII-GFPCre
targeting vector (pgpII-GFPCre TV4) and the targeted gpIIb allele (gpIIbGFPCre knockin). The black boxes represent exons. The restriction
endonuclease sites ScaI (S), HindIII (H), BamHI (B), PstI (P), and EcoRI (E) are depicted. The pgpII-GFPCre TV4 targeting vector contains a
cassette consisting of a splice acceptor (SA), an internal ribosomal entry site (IRES), and GFPCre sequences. It also contains a neo resistance
cassette (PGK-neo) flanked by FRT sites and an HSV-tk cassette for negative selection. The 700 bp EcoRI-HindIII promoter fragment used
for detecting targeted events by Southern blot hybridization is indicated (Probe).
(B) Southern blots of ScaI digests of genomic DNA from wild-type ES cells and the two targeted gpIIbGFPCre clones (C2 and B3) which were
used to generate the gpIIbGFPCre lines. When hybridized with the EcoRI-HindIII probe, the 11.6 kbp targeted ScaI fragment is detected in addition
to the 7.5 kbp wild-type ScaI fragment.
(C) Flow cytometric analysis of CD41 expression on bone marrow cells from wild-type (gpIIbwt/wt, left panels) and gpIIb knockout (gpIIbGFPCre/GFPCre,
right panels). Cells were either analyzed directly after collection (upper panels) or after culturing under conditions to favor outgrowth of
megakaryocytic cells (lower panels). Cells were labeled with a monoclonal antibody specific for CD41 and the appropriate secondary reagent
(solid lines) or with an isotype control (dashed lines).
Increase in Functional Progenitors in gpIIbGFPCre/GFPCre when comparing adult spleen cells derived from wild-
type and gpIIbGFPCre/GFPCre animals (data not shown).Hematopoietic Tissues
To date, no functional relevance has been ascribed to One of our concerns was that the anemia and throm-
bocytopenia seen in some of the gpIIbGFPCre/GFPCre animalsthe expression of GPIIb on hematopoietic progenitors.
The gpIIbGFPCre/GFPCre mice provide a unique means of in- might result in an increase in growth factors such as
erythropoietin and thrombopoietin which might influ-vestigating the consequences of the loss of GPIIb. We
assessed hematopoietic progenitors by in vitro colony- ence hematopoiesis in general. We addressed this issue
by comparing progenitor numbers from wild-type boneforming unit (CFU) assays in methylcellulose under con-
ditions which allow growth of all myeloid progenitors. marrow (n  8; RBC count 7.52  0.8 106/mm3; platelet
count 740  186 103/mm3) with samples taken fromWe grouped CFU-GM, CFU-G, CFU-M, and CFU-Mix
as “CFU-Myeloid”. To our surprise, we discovered mutant mice with little or no overt blood cell deficit (n 
9; RBC count 6.69 1.2 106/mm3; platelet count 573 80a consistent 1.5- to 2-fold increase in all types of hema-
topoietic progenitors in the adult bone marrow of 103/mm3) and from those few showing various degrees of
anemia and thrombocytopenia (n 2; RBC count 4.80gpIIbGFP-Cre/GFPCre animals compared to their matched wild-
type siblings (Figure 5A). This difference was observed 2.4 106/mm3; platelet count 103  86 103/mm3) and saw
the same changes between wild-type and knockout asirrespective of the blood status of the animals (Figure
5B). We did not observe any skewing in the types of described above (Figure 5B). In addition, we examined
the bone marrow from mutant mice which had nearcolony arising from gpIIbGFPCre/GFPCre bone marrow cells,
but we did notice a consistent increase in the size of normal blood values using Ter119 in combination with
CD71 (TfR) to determine the distribution of cells withinthe colonies arising from mutant cells (average diameter
of a d14 CFU-Mix was 1.4 mm and 2.1 mm in assays of the erythroid lineage. This in fact showed some evidence
for compensation in that the ratio of reticulocytes/latewild-type and mutant cells, respectively). We also saw
a 1.5-fold increase in CFU numbers and colony size erythroblasts to more immature stages was increased
Immunity
38
Figure 5. Increase in Functional Progenitors in gpIIbGFPCre/GFPCre Animals
(A) Representative assay of colony-forming units (CFU) in gpIIbwt/wt (open bars) and gpIIbGFCre/GFPCre (black bars) bone marrow. 4  104 were
cells plated in duplicate in methylcellulose medium supplemented with 25 ng/ml of thrombopoietin (TPO). Colonies were counted at days 5
(BFU-E), 8 (CFU-M, CFU-GM), and 12 (CFU-Mix and CFU-MK). CFU-Myeloid colonies represent all CFU-M, CFU-G, CFU-GM, CFU-Mix. Assays
were set up in duplicate from bone marrow derived from healthy wild-type and gpIIbGFCre/GFPCre littermate male mice. The error bars represent
the standard deviation between duplicates. This experiment was conducted on 23 wild-type and gpIIbGFCre/GFPCre littermates in duplicate.
(B) Representative CFU assay on bone marrow from wild-type mice (open bars) and gpIIbGFCre/GFPCre animals exhibiting anemia (black bars)
were performed as in (A). Three anemic animals were compared in this way to wild-type littermate males.
(C) Flow cytometric analysis of staining with CD71/Ter119, Mac1, or B220 and annexin V binding on bone marrow cells from wild-type (left
panels) and gpIIb knockout (right panels).
(D) Representative graph of the quantification of TPO levels in the plasma of gpIIbwt/wt and gpIIbGFCre/GFPCre mice. Three independent gpIIbGFPCre/GFPCre
animals were compared to sex- and age-matched wild-types. The error bars represent the standard deviation.
(E) Increase in the number of cells with colony-forming ability in gpIIbGFPCre/GFPCre yolk sac and fetal liver. 1–4  104 E9.5 yolk sac or E12.5,
E13.5, and E15.5 fetal liver cells from gpIIbwt/wt and gpIIbGFCre/GFPCre embryos were assayed for CFU as described in (A). Each bar represents the
mean CFU number obtained by comparing two embryos of each genotype from the same litter. One experiment out of three is illustrated.
(F) Restoration of CD41 expression on gpIIbGFPCre/GFPCre cells following removal of the neo cassette with FlpE recombinase. The histograms
represent the percentage of bone marrow cells staining positively for CD41 expression. gpIIbwt/wt (open bars), gpIIbGFCre/GFPCre (black bars), and
gpIIbGFPCreneo/GFPCreneo (gray bars).
(G) Restoration of CFU numbers in gpIIbGFPCreneo/GFPCreneo bone marrow. The histogram shows the results of CFU assays of cells as described
in (A) performed on bone marrow from gpIIbwt/wt (open bar), gpIIbGFPCre/GFPCre (black bar), and gpIIbGFPCreneo/GFPCreneo (gray bar) animals.
(H) Increase in spleen colony-forming units (CFU-S10) in gpIIbGFPCre/GFPCre bone marrow cells. 4  104 bone marrow cells from gpIIbwt/wt or
gpIIbGFPCre/GFPCre male littermates were injected intravenously into three lethally irradiated recipients. The spleens were removed and analyzed
for macroscopic colonies after 10 days. A single spleen colony was detected in a control group of animals (n  4) which received no injection
of bone marrow cells. Two independent experiments are illustrated. The error bars represent the standard deviation in the group of three
injected animals per point.
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in knockout mice compared to the wild-type (Figure 5C, Adhesion to Fibronectin Contributes to the Influence
of GPIIb on Progenitor Cell Numbersupper panel). No other differences could be detected in
Since GPIIb/IIIa has been shown to be a receptor forother cell types (Figure 5C, middle panels) including any
several extracellular matrix molecules on platelets, wechange in the number of apoptotic cells as determined
investigated whether GPIIb might have an equivalentby labeling with annexin V-FITC (Figure 5C, lower panel).
role on hematopoietic progenitor cells. The latter de-It should be pointed out that no relative increase in
velop in close contact with stromal cells and extracellu-BFU-Es over other CFU colonies was observed in the
lar matrix and express a variety of adhesion receptorsknockout. Since even a mild degree of thrombocyto-
which enable them to interact with these componentspenia may have induced changes in the levels of TPO,
(Prosper and Verfaillie, 2001). Integrin receptors are in-which is known to be a potent regulator of progenitor
volved in the homing and retention of pluripotent hema-development, we measured its level by ELISA in the
topoietic progenitors in the bone marrow or other spe-blood of those animals with a mild platelet phenotype
cialized hematopoietic microenvironments (Buckley etbut were unable to detect any differences compared to
al., 1998; Verfaillie, 1998), and of the known biologicallythe wild-type (Figure 5D). Although these results do not
active ligands which bind GPIIb, likely candidates arecompletely exclude the possibility of indirect secondary
fibronectin, fibrinogen, and vitronectin. We comparedeffects in the bone marrow, they show that the increase
the CFU potential of wild-type and gpIIbGFPCre/GFPCre bonein progenitors in the gpIIb knockout bone marrow does
marrow cells following a step that would allow cells tonot appear to be caused by obvious hematopoietic com-
adhere to immobilized potential ligands. Following a redpensation.
cell lysis step, 1  106 freshly harvested bone marrowNext we determined whether an increase in myeloid
cells were plated on either a bone marrow-derived stro-progenitors could also be seen during embryonic devel-
mal layer or surfaces coated with the purified ligandsopment. CFU assays were performed using cells from
fibronectin, vitronectin, or fibrinogen. After 6 hr, the ad-E9.5 yolk sac and E12.5, E13.5, and E15.5 fetal liver.
herent and nonadherent fractions were separately col-Again, we observed a consistent 1.5- to 2-fold increase
lected and plated at equal cell densities into in vitroin all myeloid colonies without any shift in colony type.
CFU assays. Under these conditions, the stromal and
The differences between wild-type and gpIIbGFPCre/GFPCre
fibronectin-adherent portion of wild-type bone marrow
were greater at E9.5 and E13.5 (Figure 5E). As in the
cells showed a selective enrichment for all myeloid pro-
case of gpIIbGFPCre/GFPCre bone marrow, the colonies arising
genitors, which was lost from the gpIIbGFPCre/GFPCre cells
from gpIIbGFPCre/GFPCre progenitor cells in the yolk sac and (Figure 6A). No difference was seen between wild-type
fetal liver were larger than in the wild-type assays. Re- and gpIIbGFPCre/GFPCre cells after allowing adhesion to fi-
flecting the results with bone marrow, we were unable brinogen or vitronectin, therefore showing that specific
to detect any changes in the overall cellular content of adhesion to fibronectin was involved.
E13.5 gpIIbGFPCre/GFPCre fetal liver, but in addition in the
latter there were no perturbations to the balance of cells GPIIb Modulates the Functions of the VLA-4
within the erythroid lineage (data not shown) and VLA-5 Fibronectin Receptors
In order to investigate the effect of restoring GPIIb Since VLA-4 (41) VLA-5 (51) have been shown to be
expression from the gpIIbGFPCre allele, we removed the important adhesion receptors for fibronectin (Williams
double FRT-flanked PGK-neo resistance cassette by et al., 1991; Kerst et al., 1993; Papayannopoulou and
Flp-mediated recombination (Dymecki, 1996). Flow Nakamoto, 1993; Hurley et al., 1995; Craddock et al.,
cytometric analysis of CD41 expression on bone marrow 1997; Papayannopoulou et al., 2001), we investigated
cells from gpIIbGFPCreneo/GFPCreneo animals revealed that whether the loss of GPIIb on gpIIbGFPCre/GFPCre cells was
GPIIb levels were restored to normal (Figure 5F). Corre- related to changes in the expression of these receptors.
spondingly, the 1.5- to 2-fold increase in the number of Flow cytometric analysis of VLA-4 and VLA-5 on bone
progenitors seen in gpIIbGFPCre/GFPCre bone marrow was marrow cells revealed no differences between wild-type
lost in gpIIbGFPCreneo/GFPCreneo animals (Figure 5G). and mutant cells (Figure 6B). We performed blocking
experiments using specific antibodies against these two
integrins to determine whether they are solely responsi-
Increase in CFU-S10 Multipotential Progenitors ble for binding to fibronectin or whether GPIIb could be
in gpIIbGFPCre/GFPCre Bone Marrow directly involved as well. We incubated bone marrow
To specifically address the question of the effect of cells with either anti-VLA-4, anti-VLA-5, or matched iso-
GPIIb expression on multipotential progenitors we used type control antibodies for 30 min on ice prior to the
the in vivo colony-forming unit-spleen (CFU-S) assay adhesion step. The results of the CFU assays using
(Till and McCulloch, 1961). We injected 4  104 wild- these cells showed that in addition to decreased adhe-
type or gpIIbGFPCre/GFPCre bone marrow cells intravenously sive capacity of mutant cells to fibronectin they had lost
into host animals that had been lethally irradiated. most of their binding that could be inhibited by anti-
Spleens were isolated after 10 days and the number of VLA-4 and anti-VLA-5 (Figure 6C), implying a role for
nodules, representing expansion from a single CFU-S, GPIIb in modulating the function of VLA-4 and VLA-5.
were counted after fixation. As in the in vitro assays,
we observed a 2-fold or greater number of progenitors Discussion
capable of generating spleen colonies in the bone mar-
row of gpIIbGFPCre/GFPCre animals compared to wild-type Several questions arise out of the observations that
GPIIb is expressed on hematopoietic progenitors. First,(Figure 5H).
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Figure 6. Loss of Fibronectin-Adherent Progenitors in gpIIbGFPCre/GFPCre Bone Marrow
(A) Adhesion of bone marrow progenitors to stroma or purified fibronectin is significantly lower for cells derived from gpIIbGFPCre/GFPCre compared
to wild-type. 1  106 unfractionated bone marrow cells were plated on stroma, purified adhesive ligands, or bovine serum albumin (BSA)
control for 6 hr in Tyrode’s Buffer (pH 7.3). The adherent and nonadherent fractions were collected separately, and 1  104 cells were replated
in methylcellulose for assay of CFU numbers. The total number of colonies obtained from both fractions was scored after 14 days. The data
is represented as the percentage of adherent CFU ([number of CFU in adherent fraction/number of CFU in adherent nonadherent fractions]
100). One out of three experiments is represented. The error bars represent the standard deviation between duplicates.
(B) Two-color flow cytometric analysis of gpIIbwt/wt and gpIIbGFPCre/GFPCre bone marrow cells using monoclonal antibodies which specifically
recognize CD34, 4 integrin (CD49d), and 5 integrin (CD49e), showing that there is no significant difference between the wild-type and mutant
animals.
(C) Representative anti-4 and anti-5 integrin blocking experiment. gpIIbGFPCre/GFPCre cells appear to have lost the adhesive functions of VLA-4
and VLA-5. 1–2  106 unfractionated bone marrow cells were preincubated on ice for 30 min with 10 	g/ml of either anti-mouse CD49d (anti-4
PharMingen 01271 D), its isotype control anti-IgG2b (PharMingen), anti-mouse CD49e (anti-5 PharMingen 553319), or its isotype control anti-
IgG2a (PharMingen). The bone marrow cells were then allowed to adhere to purified fibronectin or BSA control and the CFU potential of the
adherent and nonadherent fractions was assayed as described above. One out of three experiments is represented. The error bars represent
the standard deviation between duplicates.
how early in the process of hematopoietic commitment dermal lineages; therefore, GPIIb may be expressed at
an important developmental junction. Second, do hema-is GPIIb expressed? Several markers of hematopoietic
progenitors are also detected in endothelial cells, per- topoietic progenitors at all developmental stages ex-
press GPIIb equally? There is already some evidencehaps reflecting the common origin of these two meso-
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that this is not the case (Debili et al., 2001); however, it ever, only a small proportion of hematopoietic cells (2%
to 3%) exhibited the recombined phenotype in adultis not clear, for instance, whether GPIIb is expressed
on primitive hematopoietic progenitors. Finally, what bone marrow. This suggests that cells marked by Cre
expression from the gpIIb-Cre transgene do not ulti-function, if any, can be ascribed to GPIIb on hematopoi-
etic progenitors, and is this equivalent at all those devel- mately give rise to the whole of the adult hematopoietic
system and that a separate wave of definitive hemato-opmental stages at which it is expressed? We have
sought to address these questions using a combination poiesis is either present concurrently or arises later in
the fetus. Our experiments do not allow us to distinguishof lineage tracing and analysis of hematopoietic progen-
itors lacking GPIIb. between these possibilities. Interestingly, distinct classes
of GPIIb-expressing progenitors at different stages of
development are also proposed by Debili et al. (2001),Expression of Cre from the gpIIb-Cre Transgene
who showed that sorted neonatal and adult bone mar-Defines a Fetus-Restricted Hematopoietic
row CD41 cells were not necessarily equivalent.Progenitor Population
An additional exciting implication is that we may haveLineage tracing is a powerful way of following cell fate
identified elements which regulate gene transcriptionduring development and in the last few years a new
of gp11b in early hematopoietic progenitors. Althoughapproach has been to apply the Cre-LoxP recombina-
megakaryocyte-specific regulation of the gpIIb promotertion system for this purpose (e.g., Jiang et al., 2000). To
has been studied quite extensively (Kaluzhny et al.,apply this strategy to the question of the sites of GPIIb
2001), there is no data presently relating to control ele-expression, we have utilized a gpIIb-driven Cre line in
ments operating in progenitor cells. Our results suggestconjunction with the R26R reporter line in which Cre-
that the promoter and intron sequences present in themediated recombination results in permanent activation
gpIIb-Cre transgene are sufficient for expression in aof a lacZ gene (Soriano, 1999). We believe that the gpIIb-
subset of definitive hematopoietic progenitors but thatCre transgenic line recapitulates the early expression
additional elements may be required for expression inpattern of the gpIIb gene on hematopoietic progenitors
either progenitors that give rise to the majority of adultbecause of colocalization of GPIIb protein, Cre protein,
hematopoiesis or in megakaryocytes.and the earliest detectable sites of Cre activity as re-
vealed by the presence of -galactosidase. Our data
GPIIb Plays a Role in the Regulationfrom recombination of the R26R allele in gpIIb-Cre::R26R
of Hematopoietic Progenitorsmice suggests that the transgene is not active in progen-
The functional significance of GPIIb expression on he-itors of primitive hematopoiesis since we could not de-
matopoietic progenitors has, until now, been unknown.tect -galactosidase in nucleated erythrocytes. How-
Our findings show that in the absence of GPIIb there isever, once circulation is established, Cre is clearly active
a 1.5- to 2-fold increase in the number of progenitorsin hematopoietic progenitors of the yolk sac, AGM, and
in hemogenic sites throughout development, suggestingfetal liver, and the descendants of these cells could be
a potential inhibitory role of GPIIb. Although the percent-traced to both the myeloid and lymphoid lineages in the
age of GPIIb-expressing cells is higher during develop-fetal liver, spleen, thymus, and bone marrow. Restricted
ment than in the adult bone marrow (12% in E9.5 yolkclusters of -galactosidase-positive cells were also
sac, 4% in E12.5 fetal liver, and 2%–3% in the adultfound in close association with the inner layer of the
bone marrow), cell sorting data from Corbel and Salaunendothelium of blood vessels from E9.5. These were
(2002) show that the actual percentage of GPIIbc-Kitmainly located on the ventral side of the major arteries,
cells is similar in E13.5 fetal liver and adult bone marrowwhich reflected earlier descriptions of GPIIb expression
(1.2% compared to 0.9%, respectively). Similarity at thisin the aorta in the chick (Ody et al., 1999) and the mouse
level might therefore account for the consistent 1.5- to(Corbel and Salaun, 2002). These intraembryonic clus-
2-fold increase that we observed in the gpIIb knockoutters are currently believed to represent the main source
fetus and adult. Our studies do not address whetherof definitive hematopoietic stem cells (Manaia et al.,
these observations are a reflection of differences in the2000) and to be the source of cells populating the fetal
developmental functionality of GPIIb-expressing cells,liver (Cumano and Godin, 2001; de Bruijn et al., 2000;
although previous studies by Debili et al. (2001) haveGarcia-Porrero et al., 1998; Godin et al., 1999). As de-
shown that CD34CD41 bone marrow cells have ascribed previously (Corbel and Salaun, 2002), detection
more restricted potential than those derived from cordof CD45 expression on the -galactosidase-positive
blood.clusters confirmed their hematopoietic identity although
not all -galactosidase-positive clusters were CD45
(data not shown). These observations suggest that ex- Loss of GPIIb Affects the Binding of VLA-4
and VLA-5 to Fibronectinpression of GPIIb precedes or coincides with that of
CD45 in definitive hematopoietic progenitors. We suggest that GPIIb plays a role in modulating the
adhesion of progenitors to fibronectin on stromal cellsAn interesting observation deriving from the lineage
tracing experiments is that the majority of adult hemato- and in the extracellular matrix. An extensive network of
stromal cells and extracellular matrix ligands present inpoietic cells from gpIIb-Cre::R26R mice did not contain
a recombined R26R allele. Hence, at least 60%–90% of bone marrow “niches” (Dexter et al., 1990) support stem
cell growth, differentiation, and survival (Williams, 1993;gpIIb-Cre::R26R E12.5 or E14.5 fetal liver cells contained
the recombined R26R allele, while just prior to birth, Verfaillie et al., 1999). In this context, the interaction
of hematopoietic progenitors with fibronectin throughrecombination was evident in 15% to 55% of hematopoi-
etic cells in the bone marrow, spleen, and thymus. How- integrin receptors has been extensively studied (Hurley
Immunity
42
Figure 7. Model for the Role of GPIIb on He-
matopoietic Progenitors
Multipotential progenitors home to the bone
marrow where GPIIb, through the modulation
of VLA-4 and VLA-5, is responsible for their
targeting/retention into specialized bone
marrow niches where their number is regu-
lated, through inhibition of proliferation or by
apoptosis. In the absence of GPIIb, an impor-
tant component in the regulation of progeni-
tor cell number is lost which results in an
increase in multipotential progenitors in the
gpIIbGFPCre/GFPCre knockout.
and the modified first intron of the gpIIb gene to facilitate releaseet al., 1995; Kerst et al., 1993; Verfaillie et al., 1991;
of the 8.0 kbp transgene. Purified DNA was injected into the maleWeinstein et al., 1989; Williams et al., 1991). Several
pronuclei of oocytes. The transmission of the transgene was con-attachment sites to fibronectin have been defined, and
firmed by PCR detection of Cre sequences in DNA from tail biopsies
it is known that adhesion to fibronectin may directly alter (Cre5
 TCGATGCAACGAGTGATGAG and Cre3
 TTCGGCTATACG
both cell proliferation (in positive and negative ways) TAACAGGG). Transgene copy number of gpIIb-Cre founders was
determined by Southern blotting of EcoRI-digested DNA using a(Arroyo et al., 1999; Hurley et al., 1995; Verfaillie and
gpIIb exon 1-specific probe which identifies a 1.2 kbp fragment.Catanzaro, 1996) and apoptosis (Wang et al., 1998).
Our results show that bone marrow cells lacking GPIIb
cannot be selectively enriched for myeloid progenitors
Targeting Vector Construction
by adhesion to a marrow-derived stromal layer or to A 129/SvEv mouse phage genomic library (Stratagene Inc.) was
purified fibronectin. This difference in behavior between screened using a probe encompassing the promoter region of gpIIb
from548 to1 bp (Denarier et al., 1993). A 12 kbp HindIII fragmentwild-type and gpIIbGFPCre/GFPCre cells was not seen when
encompassing 6 kbp of the gpIIb promoter, exon 1, and about 5 kbpthe bone marrow cells were plated either on vitronectin
of intron 1 was ligated into pBluescript IISK. The targeting constructor fibrinogen. The loss of GPIIb seems to affect the
was made by insertion into intron 1 of a 3.8 kbp cassette consistingfunctionality of the major integrin receptors for fibronec-
of the GFPCre fusion from pBS558 (Gagneten et al., 1997) flanked
tin, VLA-4 (41) and VLA-5 (51), without altering their by a splice acceptor-IRES fusion on the 5
 side from pGTIRESgeo
expression levels. Antibodies against VLA-4 and VLA-5 (Mountford et al., 1994) and by an SV40 polyadenylation site on the
3
 end. A fragment containing the neomycin resistance gene drivenwere able to diminish the ability of wild-type but not
by the PGK promoter from the pPNT plasmid (Tybulewicz et al.,mutant progenitor cells to bind to fibronectin. Crossinte-
1991) was flanked by FRT sites and inserted downstream of thegrin modulation of binding affinities is a well-described
GFPCre cassette in the gpIIb intron 1. A tk gene driven by the mousephenomenon (Anzai et al., 1999; Wagers et al., 2002),
PGK promoter from pPNT (Tybulewicz et al., 1991) was inserted at
and our results point to the possibility that GPIIb plays the 3
 end of the targeting vector, and unique FseI and NotI sites
such role on the binding of VLA-4 and VLA-5 to fibronec- were introduced to facilitate linearization yielding the 20.4 kbp tar-
geting vector pgpII-GFPCreTV4.tin. 1 integrins have been shown to be involved in a
cell cycle block at the G1/S phase (Hurley et al., 1995,
1997), and in addition, as we have observed, increased
ES Cell Targeting and Generation of gpIIbGFPCre Miceproliferation of hematopoietic progenitors was demon-
The linearized pgpII-GFPCReTV4 vector (50 	g) was electroporated
strated when direct contact between progenitors and (240 V, 500 	F) into 1  107 TL1 129SvEv ES cells and maintained
stromal cells was prevented (Verfaillie, 1992; Hurley et as described previously (Winnier et al., 1995). Three hundred sixteen
colonies resistant to G418 (280 	g/ml) and gancyclovir (0.2 	M)al., 1995; Verfaillie and Catanzaro, 1996). We therefore
selection were isolated 7 days after electroporation. Homologousspeculate that GPIIb, by modulating the VLA-4- and
recombination was detected by Southern blot hybridization of ESVLA-5-dependent response of hematopoietic progeni-
clone DNA digested with ScaI or BstXI, using a combination of 5
tors to fibronectin, mediates the anchoring of hemato-
and 3
 probes which contain sequences external to the targeting
poietic cells to the bone marrow niche, which, either vector sequences. An internal neo probe, which recognizes only the
directly or indirectly, contributes to an inhibition of prolif- targeted allele, was used to further confirm the identity of targeted
events. Correctly targeted events occurred at a frequency of 1 ineration of progenitors (Figure 7).
20. Two positive ES cell clones (C2 and B3) were injected into
3.5 day blastocysts harvested from superovulated C57BL/6 donors.Experimental Procedures
Germline transmission was evaluated by backcrossing the resultant
chimeras to C57BL/6 mice. The C2 and B3 chimeras gave rise toTransgene Construction and Generation of Transgenic Animals
independent gpIIbGFPCre lines, which are indistinguishable. All theCre coding sequences were amplified by PCR using pMC-Cre (Gu
results described in this paper are taken from the C2 line.et al., 1994) as template with the SV40 nuclear localization signal
gpIIbwt/GFPCre heterozygotes, originally on a 129Sv background,(NLS) fused to it using the primers CreI GTTAATTAAATGCC
were maintained by backcrossing to C57BL/6. Genotyping to dis-TAAAAAAAAAAGGAAAGTGTCCAATTTACTGAC and CreII TTAAT
criminate gpIIbGFPCre from gpIIb used primers that amplify 500 bp ofTAATGGCTAATCGCCATCTTCC. The NLS-Cre fusion was then
the coding sequence for Cre as described above in conjunctioncloned into the first intron of the gpIIb gene flanked on the 5
 side
with primers that amplify 435 bp of intron 1 of the gpIIb gene (CAGby a fusion of the mouse engrailed-2 protein splice acceptor (SA)
ACTCCTGGCTCATCTAC and TCTGCCTAACTCTGCTTTCC). Theand the ECMV IRES from pGTIRESgeo (Mountford et al., 1994) and
gpIIbGFPCre/GFPCre embryos were produced by mating gpIIb/GFPCre het-by an SV40 polyadenylation site on the 3
 end to give rise to the
erozygotes, the morning of appearance of vaginal plugs being setgpIIb-Cre. Two artificial NotI sites were inserted at either end of the
construct, which encompasses 3.0 kbp of the promoter, first exon, as day 0.5.
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Determination of R26R Recombination by Southern Blotting lateral tail vein. After 10 days the mice were sacrificed and their
spleens were removed and fixed in Tellesniczky’s fixative. ColoniesDNA was extracted from the fetal livers, hind limbs, and tails of
E12.5 and E14.5 gpIIb-Cre::R26R embryos or bone marrow (with were counted after 2 hr of fixation.
red cell lysis) of adult gpIIb-Cre::R26R. Twenty micrograms of geno-
mic DNA was digested with EcoRV, run on an agarose gel, and Quantification of Thrombopoietin
transferred onto a nitrocellulose membrane which was probed with Age- and sex-matched wild-type and gpIIbGFPCre/GFPCre adults were
a 500 bp fragment for the ROSA26 locus. In addition to the 11 kbp sacrificed, and blood was collected in acid citrate buffer. The sam-
wild-type ROSA allele, this probe recognizes the mutated 3.8 kbp ples were spun to remove the cellular content, and the plasma was
allele and the recombined 3.3 kbp R26R allele. prepared according to the manufacturer’s instructions (Quantikine
M Murine TPO Detection Kit; R&D Laboratories) to determine TPO
Histological Staining and Sectioning levels by immunoassay. The plate was then read at A450 with a
Embryos were dissected out at various stages of gestation and fixed correction wavelength of A540.
in 0.4%–4% paraformaldehyde for 30 min to 4 hr depending on their
size. The embryos were then washed in PBS and dehydrated in a Adhesion Assay
methanol gradient prior to further processing or sectioning. Whole- Adhesive substrata were prepared from bone marrow-derived stro-
mount -galalctosidase staining was performed as described pre- mal cells plated at subconfluent density on 6 cm dishes. Alterna-
viously (Hogan et al., 1994), and 0.2 	m sections were obtained and tively, the plates were coated with 5 	g/ml fibronectin, fibrinogen,
lightly counterstained with eosin. or vitronectin (Sigma) in PBS for 2 hr at 37C. After washing in PBS,
the plates containing the purified ligands were then blocked in 3%
Whole-Mount Antibody Staining BSA in PBS for an hour at 37C. 1–2  106 freshly harvested bone
Following dehydration and rehydration, fixed embryos were marrow cells following red cell lysis were plated on the various
bleached in 3% hydrogen peroxide for 10 min. After washing in PBS substrata on 6 cm plates in Tyrode’s Buffer (134 mM NaCl, 2.9 mM
containing 0.2% BSA and 0.1% Triton X-100, the embryos were KCl, 0.34 mM Na2HPO4.12H2O, 12 mM NaHCO3, 20 mM HEPES,
blocked in 5% goat serum and incubated at room temperature over- 1 mM MgCl2, 1.5 mM CaCl2 [pH 7.3]) and allowed to adhere for 6 hr.
night with a 1:300 dilution of a polyclonal Cre antibody (Babco PRB- The nonadherent fraction was then harvested with two consecutive
106C) or a polyclonal CD41 antibody (Santa Cruz, sc-6602). The gentle washes in warm PBS while the adherent fraction was briefly
embryos were then washed and incubated with a secondary goat- trypsinized. The nonadherent fraction was also briefly trypsinized
anti-rabbit or rabbit anti-goat antibody linked to alkaline phospha- so that the two fractions had been treated equally. After washing,
tase (DAKO) at a 1:50 dilution for 1 hr at room temperature. After the cells were resuspended in PBS and counted, and 2–4  104
washing, the specimens were developed using NBT/BCIP (Roche). cells from both fractions were plated in methylcellulose. The total
number of myeloid colonies (BFU-E, CFU-M, -G, -GM, -MK, and
-Mix) was scored 12–14 days after plating.Immunohistochemistry for Cre Recombinase
on Paraffin Sections
Dewaxed sections were bleached in 3% hydrogen peroxide for 30 Antibody-Blocking Assays
min, blocked in 1% normal goat serum, and incubated for 30 min at 1–2  106 freshly harvested bone marrow cells following red cell
room temperature with a 1:300 dilution of a polyclonal Cre antibody lysis were incubated on ice for 30 min with 10	g/ml integrin-specific
(Babco PRB-106C). After washing, the slides were then incubated blocking antibody or matched isotype controls: anti-VLA-4 (CD49d,
with a secondary anti-rabbit biotinylated antibody for 30 min at clone R1-2), anti-rat IgG2b, anti-VLA-5 (CD49e, clone 5H10), anti-rat
room temperature and developed using the VIP reagent (Vector IgG2a (all from PharMingen). The cells were then plated on purified
Laboratories). fibronectin in Tyrode’s Buffer and allowed to adhere as described
above. The nonadherent and adherent fractions were separately
harvested and treated in a similar way. The cells were then countedImmunofluorescent Staining and Flow Cytometry
and set up in CFU assays, and colonies were counted after 7 days.Single-cell suspensions of bone marrow or fetal liver were prepared
by standard techniques. Red cells were depleted from the prepara-
tions by lysis in ACK buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Acknowledgments
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